Clinical Trial Update: Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update evaluating rivaroxaban versus low-molecular-weight heparin for preventing thrombosis in cancer patients (Phase 1/2) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Capital Medical University | Conditions: Neoplasms | Phase 1, Phase 2 | Status: COMPLETED